Browsing Tag
Eli Lilly and Company
176 posts
Novo Nordisk licenses Hengrui weekly oral GLP-1/GIP drug in deal worth up to $2.6bn
HRS-1596 adds an oral GLP-1/GIP dual agonist to Novo Nordisk’s external pipeline only days after the company licensed technology aimed at monthly and quarterly injections.
Novo Nordisk signs €1.17bn Nanexa deal targeting monthly obesity injections
Novo Nordisk has licensed Nanexa's PharmaShell platform for as many as five programmes as competition shifts from weight loss alone toward convenience and dosing frequency.
Eli Lilly signs InnoCare drug discovery deal worth up to $3.35bn
The partnership covers as many as five drug targets, with most of the headline value dependent on development and commercial milestones.
FDA approves Eli Lilly’s Inluriyo-Verzenio combination for ESR1-mutated breast cancer
The United States Food and Drug Administration has approved Inluriyo with Verzenio for a genetically defined form of advanced breast cancer after endocrine therapy. In a 159-patient analysis, median progression-free survival reached 11.1 months with the combination versus 5.5 months with Inluriyo alone, expanding Eli Lilly's ability to pair two medicines from its own oncology portfolio.
Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next
Eli Lilly and Company’s retatrutide programme has completed the core Phase 3 clinical package supporting planned submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea. The investigational triple hormone receptor agonist is moving toward a U.S. filing in the first quarter of 2027 while additional studies test diabetes, cardiovascular and kidney outcomes, liver disease, chronic pain, maintenance treatment and its performance against tirzepatide.
Novo Nordisk’s $1.4bn Orbis deal pushes obesity drug race deeper into oral medicines
Novo Nordisk has signed a discovery and licensing agreement worth up to $1.4 billion with Orbis Medicines to develop orally available macrocycle therapies for cardiometabolic disease, extending the Wegovy maker’s strategy beyond injectable GLP-1 drugs and its existing oral semaglutide technology.
Superluminal lands $60m Series B to take genetic obesity drug into human trials
Superluminal Medicines has secured an oversubscribed $60 million Series B to move a selective small-molecule MC4R agonist into Phase 1, entering an obesity niche where Rhythm Pharmaceuticals already generates more than $70 million a quarter.
Moonwalk Biosciences secures $70m Series B for adipose-targeted RNAi
Moonwalk Biosciences has secured $70 million to advance MW101 toward human testing, taking disclosed financing since launch to $127 million as the biotech pursues an adipose-targeted alternative to appetite-based obesity therapies.
Elecsys pTau217 wins FDA clearance as Roche pushes Alzheimer’s testing into primary care
Roche has secured FDA clearance for Elecsys pTau217, giving more than 4,500 existing U.S. cobas analyzers a potential role in assessing Alzheimer’s amyloid pathology through a routine blood draw.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.